Bone and skeletal muscle: Key players in mechanotransduction and potential overlapping mechanisms

Bone

Volumn 80, Issue , 2015, Pages 24-36

  Goodman, Craig A ^a,b   Hornberger, Troy A ^a   Robling, Alexander G ^c,d,e  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b VICTORIA UNIVERSITY   (Australia)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Indiana University Purdue University Indianapolis   (United States)

Author keywords

Bone mineral density; Growth; Hypertrophy; Mechanical loading; MTORC1

Indexed keywords

7 NITROINDAZOLE; BETA CATENIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE ALPHA; DIACYLGLYCEROL KINASE; DIACYLGLYCEROL KINASE ZETA; G PROTEIN COUPLED RECEPTOR; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE THETA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D1; POLYCYSTIN 1; POLYCYSTIN 2; PROSTAGLANDIN E2; PROTEIN KINASE B; REACTIVE NITROGEN SPECIES; RHEB PROTEIN; SOMATOMEDIN C; TUBERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 4; WNT7B PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

BONE; CALCIUM CELL LEVEL; CELL SHAPE; CELL SIZE; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME SYNTHESIS; EXERCISE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MECHANOTRANSDUCTION; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; OSTEOBLAST; OSTEOCYTE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; QUALITY OF LIFE; REVIEW; RNA TRANSLATION; SATELLITE CELL; SKELETAL MUSCLE; WNT SIGNALING PATHWAY; ANIMAL; BONE DENSITY; CYTOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE DENSITY; HUMANS; MECHANOTRANSDUCTION, CELLULAR; MULTIPROTEIN COMPLEXES; MUSCLE, SKELETAL; TOR SERINE-THREONINE KINASES;

EID: 84943631887     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.04.014     Document Type: Review

References (229)

1. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012, 8:457-465.
2. Yang J. Enhanced skeletal muscle for effective glucose homeostasis. Progress in molecular biology and translational science 2014, 133-163. Academic Press. T. Ya-Xiong (Ed.).
3. Wolfe R.R. The underappreciated role of muscle in health and disease. Am J Clin Nutr 2006, 84:475-482.
4. DiGirolamo D.J., Kiel D.P., Esser K.A. Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res 2013, 28:1509-1518.
5. Karsenty G., Oury F. Biology without walls: the novel endocrinology of bone. Annu Rev Physiol 2012, 74:87-105.
6. DiGirolamo D.J., Clemens T.L., Kousteni S. The skeleton as an endocrine organ. Nat Rev Rheumatol 2012, 8:674-683.
7. Schiaffino S., Dyar K.A., Ciciliot S., Blaauw B., Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013, 280:4294-4314.
8. Robling A.G. The interaction of biological factors with mechanical signals in bone adaptation: recent developments. Curr Osteoporos Rep 2012, 10:126-131.
9. Goodman C.A. The role of mTORC1 in regulating protein synthesis and skeletal muscle mass in response to various mechanical stimuli. Rev Physiol Biochem Pharmacol 2014, 166:1-53.
10. Adams G.R., Bamman M.M. Characterization and regulation of mechanical loading-induced compensatory muscle hypertrophy. Compr Physiol 2012, 2:2829-2870.
11. Hornberger T.A. Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. Int J Biochem Cell Biol 2011, 43:1267-1276.
12. Arfat Y., Xiao W.-Z., Iftikhar S., Zhao F., Li D.-J., Sun Y.-L., et al. Physiological effects of microgravity on bone cells. Calcif Tissue Int 2014, 94:569-579.
13. Klein-Nulend J., Bacabac R.G., Bakker A.D. Mechanical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton. Eur Cell Mater 2012, 24:278-291.
14. Robling A.G., Turner C.H. Mechanical signaling for bone modeling and remodeling. Cirt Rev Eukaryot Gene Expr 2009, 19:319-338.
15. Lu T.W., Taylor S.J., O'Connor J.J., Walker P.S. Influence of muscle activity on the forces in the femur: an in vivo study. J Biomech 1997, 30:1101-1106.
16. Burr D.B. Muscle strength, bone mass, and age-related bone loss. J Bone Miner Res 1997, 12:1547-1551.
17. Rodríguez J.I., Garcia-Alix A., Palacios J., Paniagua R. Changes in the long bones due to fetal immobility caused by neuromuscular disease. A radiographic and histological study. J Bone Joint Surg Am 1988, 70:1052-1060.
18. Rodríguez J., Palacios J., García-Alix A., Pastor I., Paniagua R. Effects of immobilization on fetal bone development. A morphometric study in newborns with congenital neuromuscular diseases with intrauterine onset. Calcif Tissue Int 1988, 43:335-339.
19. Sharir A., Stern T., Rot C., Shahar R., Zelzer E. Muscle force regulates bone shaping for optimal load-bearing capacity during embryogenesis. Development 2011, 138:3247-3259.
20. Hall B.K., Herring S.W. Paralysis and growth of the musculoskeletal system in the embryonic chick. J Morphol 1990, 206:45-56.
21. Hall J.G. Importance of muscle movement for normal craniofacial development. J Craniofac Surg 2010, 21:1336-1338.
22. Rauch F., Bailey D.A., Baxter-Jones A., Mirwald R., Faulkner R. The 'muscle-bone unit' during the pubertal growth spurt. Bone 2004, 34:771-775.
23. Rauch F., Schoenau E. Peripheral quantitative computed tomography of the proximal radius in young subjects-new reference data and interpretation of results. J Musculoskelet Neuronal Interact 2008, 8:217-226.
24. Fricke O., Beccard R., Semler O., Schoenau E. Analyses of muscular mass and function: the impact on bone mineral density and peak muscle mass. Pediatr Nephrol 2010, 25:2393-2400.
25. Larson C.M., Henderson R.C. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000, 20:71-74.
26. Tasdemir H.A., Buyukavci M., Akcay F., Polat P., Yildiran A., Karakelleoglu C. Bone mineral density in children with cerebral palsy. Pediatr Int 2001, 43:157-160.
27. Eser P., Frotzler A., Zehnder Y., Wick L., Knecht H., Denoth J., et al. Relationship between the duration of paralysis and bone structure: a pQCT study of spinal cord injured individuals. Bone 2004, 34:869-880.
28. Lang T., LeBlanc A., Evans H., Lu Y., Genant H., Yu A. Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res 2004, 19:1006-1012.
29. Schoenau E. From mechanostat theory to development of the "Functional Muscle-Bone-Unit". J Musculoskelet Neuronal Interact 2005, 5:232-238.
30. Binkley N., Krueger D., Buehring B. What's in a name revisited: should osteoporosis and sarcopenia be considered components of "dysmobility syndrome?". Osteoporos Int 2013, 24:2955-2959.
31. Goodman C.A., Mayhew D.L., Hornberger T.A. Recent progress towards understanding the molecular mechanisms that regulate skeletal muscle mass. Cell Signal 2011, 23:1896-1906.
32. Lynch G.S., Ryall J.G. Role of {beta}-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008, 88:729-767.
33. Glass D.J. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol 2010, 346.
34. Huang Z., Chen X., Chen D. Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. Cell Signal 2011, 23:1441-1446.
35. Lee N.K.L., MacLean H.E. Polyamines, androgens and skeletal muscle hypertrophy. J Cell Physiol 2011, 226:1453-1460.
36. McCarthy J.J. The MyomiR network in skeletal muscle plasticity. Exerc Sport Sci Rev 2011, 39:150-154.
37. Phillips B.E., Hill D.S., Atherton P.J. Regulation of muscle protein synthesis in humans. Curr Opin Clin Nutr Metab Care 2012, 15:58-63.
38. Schiaffino S., Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle 2011, 1:4.
39. Berdeaux R., Stewart R. cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration. Am J Physiol Endocrinol Metab 2012, 303:E1-E17.
40. Dubois V., Laurent M., Boonen S., Vanderschueren D., Claessens F. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci 2012, 69:1651-1667.
41. Piccirillo R., Demontis F., Perrimon N., Goldberg A.L. Mechanisms of muscle growth and atrophy in mammals and Drosophila. Dev Dyn 2014, 243(2):201-215.
42. Blaauw B., Reggiani C. The role of satellite cells in muscle hypertrophy. J Muscle Res Cell Motil 2014, 35:3-10.
43. McCarthy J.J., Mula J., Miyazaki M., Erfani R., Garrison K., Farooqui A.B., et al. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. Development 2011, 138:3657-3666.
44. Fornaro M., Hinken A.C., Needle S., Hu E., Trendelenburg A.U., Mayer A., et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 2015, 306(2):E150-E156.
45. O'Connor R.S., Pavlath G.K., McCarthy J.J., Esser K.A. Last word on point:counterpoint: satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. J Appl Physiol 2007, 103:1107.
46. Laplante M., Sabatini David M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
47. Mahoney S.J., Dempsey J.M., Blenis J. Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation. Prog Mol Biol Transl Sci 2009, 90C:53-107.
48. Goodman C.A., Mabrey D.M., Frey J.W., Miu M.H., Schmidt E.K., Pierre P., et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J 2011, 25:1028-1039.
49. Goodman C.A., Miu M.H., Frey J.W., Mabrey D.M., Lincoln H.C., Ge Y., et al. A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of rapamycin signaling is sufficient to induce skeletal muscle hypertrophy. Mol Biol Cell 2010, 21:3258-3268.
50. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001, 3:1014-1019.
51. Goodman C.A., Frey J.W., Mabrey D.M., Jacobs B.L., Lincoln H.C., You J.-S., et al. The role of skeletal muscle mTOR in the regulation of mechanical load-induced growth. J Physiol 2011, 589:5485-5501.
52. Perrone C.E., Fenwick-Smith D., Vandenburgh H.H. Collagen and stretch modulate autocrine secretion of insulin-like growth factor-1 and insulin-like growth factor binding proteins from differentiated skeletal muscle cells. J Biol Chem 1995, 270:2099-2106.
53. Yang S., Alnaqeeb M., Simpson H., Goldspink G. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil 1996, 17:487-495.
54. McKoy G., Ashley W., Mander J., Yang S.Y., Williams N., Russell B., et al. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 1999, 516:583-592.
55. Hameed M., Orrell R.W., Cobbold M., Goldspink G., Harridge S.D. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol 2003, 547:247-254.
56. Monier S., Le Cam A., Le Marchand-Brustel Y. Insulin and insulin-like growth factor I. Effects on protein synthesis in isolated muscles from lean and goldthioglucose-obese mice. Diabetes 1983, 32:392-397.
57. Gulve E.A., Dice J.F. Regulation of protein synthesis and degradation in L8 myotubes. Effects of serum, insulin and insulin-like growth factors. Biochem J 1989, 260:377-387.
58. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995, 270:12109-12116.
59. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., Sweeney H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 1998, 95:15603-15607.
60. Musaro A., McCullagh K., Paul A., Houghton L., Dobrowolny G., Molinaro M., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001, 27:195-200.
61. Dardevet D., Sornet C., Vary T., Grizard J. Phosphatidylinositol 3-kinase and p70 s6 kinase participate in the regulation of protein turnover in skeletal muscle by insulin and insulin-like growth factor I. Endocrinology 1996, 137:4087-4094.
62. Frost R.A., Lang C.H. Differential effects of insulin-like growth factor I (IGF-I) and IGF-binding protein-1 on protein metabolism in human skeletal muscle cells. Endocrinology 1999, 140:3962-3970.
63. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001, 3:1009-1013.
64. Latres E., Amini A.R., Amini A.A., Griffiths J., Martin F.J., Wei Y., et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005, 280:2737-2744.
65. Park I.H., Erbay E., Nuzzi P., Chen J. Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1. Exp Cell Res 2005, 309:211-219.
66. Fedele M.J., Lang C.H., Farrell P.A. Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise. Am J Physiol Endocrinol Metab 2001, 280:E877-E885.
67. Liu J.-P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
68. Martineau L.C., Gardiner P.F. Insight into skeletal muscle mechanotransduction: MAPK activation is quantitatively related to tension. J Appl Physiol 2001, 91:693-702.
69. Drummond M.J., Fry C.S., Glynn E.L., Dreyer H.C., Dhanani S., Timmerman K.L., et al. Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. J Physiol 2009, 587:1535-1546.
70. Tannerstedt J., Apro W., Blomstrand E. Maximal lengthening contractions induce different signaling responses in the type I and type II fibers of human skeletal muscle. J Appl Physiol 2009, 106:1412-1418.
71. Sasai N., Agata N., Inoue-Miyazu M., Kawakami K., Kobayashi K., Sokabe M., et al. Involvement of PI3K/Akt/TOR pathway in stretch-induced hypertrophy of myotubes. Muscle Nerve 2010, 41:100-106.
72. Miyazaki M., McCarthy J.J., Fedele M.J., Esser K.A. Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling. J Physiol 2011, 589:1831-1846.
73. Hulmi J.J., Walker S., Ahtiainen J.P., Nyman K., Kraemer W.J., Hakkinen K. Molecular signaling in muscle is affected by the specificity of resistance exercise protocol. Scand J Med Sci Sports 2012, 22:240-248.
74. You J.S., Frey J.W., Hornberger T.A. Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid. PLoS One 2012, 7:e47258.
75. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 2004, 101:13489-13494.
76. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosisand cancer pathogenesis. Cell 2005, 121:179-193.
77. Carrière A., Cargnello M., Julien L.-A., Gao H., Bonneil É., Thibault P., et al. Signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 2008, 18:1269-1277.
78. Fonseca B.D., Alain T., Finestone L.K., Huang B.P.H., Rolfe M., Jiang T., et al. Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90RSK in the control of mTORC1 protein signaling by phorbol esters. J Biol Chem 2011, 286:27111-27122.
79. Anjum R., Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008, 9:747-758.
80. Salto R., Vílchez J.D., Cabrera E., Guinovart J.J., Girón M.D. Activation of ERK by sodium tungstate induces protein synthesis and prevents protein degradation in rat L6 myotubes. FEBS Lett 2014, 588:2246-2254.
81. Fang Y., Vilella-Bach M., Bachmann R., Flanigan A., Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001, 294:1942-1945.
82. Yoon M.S., Sun Y., Arauz E., Jiang Y., Chen J. Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. J Biol Chem 2011, 286:29568-29574.
83. Avila-Flores A., Santos T., Rincon E., Merida I. Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J Biol Chem 2005, 280:10091-10099.
84. Tang W., Yuan J., Chen X., Gu X., Luo K., Li J., et al. Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway. J Biochem Mol Biol 2006, 39:626-635.
85. O'Neil T.K., Duffy L.R., Frey J.W., Hornberger T.A. The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol 2009, 587:3691-3701.
86. Foster D.A. Regulation of mTOR by phosphatidic acid?. Cancer Res 2007, 67:1-4.
87. Jaafar R., De Larichaudy J., Chanon S., Euthine V., Durand C., Naro F., et al. Phospholipase D regulates the size of skeletal muscle cells through the activation of mTOR signaling. Cell Commun Signal 2013, 11:55.
88. You J.-S., Lincoln H.C., Kim C.-R., Frey J.W., Goodman C.A., Zhong X.-P., et al. The role of diacylglycerol kinase and phosphatidic acid in the mechanical activation of mammalian target of rapamycin (mTOR) signaling and skeletal muscle hypertrophy. J Biol Chem 2014, 289:1551-1563.
89. Hornberger T.A., Chu W.K., Mak Y.W., Hsiung J.W., Huang S.A., Chien S. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proc Natl Acad Sci U S A 2006, 103:4741-4746.
90. Huang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008, 412:179-190.
91. Aspuria P.-J., Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal 2004, 16:1105-1112.
92. Long X., Lin Y., Ortiz-Vega S., Yonezawa K., Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005, 15:702-713.
93. Sato T., Nakashima A., Guo L., Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 2009, 284:12783-12791.
94. Inoki K., Li Y., Xu T., Guan K.-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003, 17:1829-1834.
95. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003, 13:1259-1268.
96. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003, 5:578-581.
97. Jacobs B.L., You J.-S., Frey J.W., Goodman C.A., Gundermann D.M., Hornberger T.A. Eccentric contractions increase TSC2 phosphorylation and alter the targeting of TSC2 and mTOR to the lysosome. J Physiol 2013, 591:4611-4620.
98. Jacobs B.L., Goodman C.A., Hornberger T.A. The mechanical activation of mTOR signaling: an emerging role for late endosome/lysosomal targeting. J Muscle Res Cell Motil 2013, 35:11-21.
99. Stephenson D.G., Lamb G.D., Stephenson G.M. Events of the excitation-contraction-relaxation (E-C-R) cycle in fast- and slow-twitch mammalian muscle fibres relevant to muscle fatigue. Acta Physiol Scand 1998, 162:229-245.
100. Armstrong R.B., Duan C., Delp M.D., Hayes D.A., Glenn G.M., Allen G.D. Elevations in rat soleus muscle [Ca2+] with passive stretch. J Appl Physiol 1993, 74:2990-2997.
101. Franco A., Lansman J.B. Stretch-sensitive channels in developing muscle cells from a mouse cell line. J Physiol 1990, 427:361-380.
102. Graves L.M., He Y., Lambert J., Hunter D., Li X., Earp H.S. An intracellular calcium signal activates p70 but not p90 ribosomal S6 kinase in liver epithelial cells. J Biol Chem 1997, 272:1920-1928.
103. Conus N.M., Hemmings B.A., Pearson R.B. Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k. J Biol Chem 1998, 273:4776-4782.
104. Kameyama T., Etlinger J.D. Calcium-dependent regulation of protein synthesis and degradation in muscle. Nature 1979, 279:344-346.
105. Sonobe T., Inagaki T., Poole D.C., Kano Y. Intracellular calcium accumulation following eccentric contractions in rat skeletal muscle in vivo: role of stretch-activated channels. Am J Physiol Regul Integr Comp Physiol 2008, 294:R1329-R1337.
106. Spangenburg E.E., McBride T.A. Inhibition of stretch-activated channels during eccentric muscle contraction attenuates p70S6K activation. J Appl Physiol 2006, 100:129-135.
107. Ito N., Ruegg U.T., Kudo A., Miyagoe-Suzuki Y., Takeda Si. Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med 2013, 19:101-106.
108. Ito N., Ruegg U.T., Kudo A., Miyagoe-Suzuki Y., Takeda Si. Capsaicin mimics mechanical load-induced intracellular signaling events: involvement of TRPV1-mediated calcium signaling in induction of skeletal muscle hypertrophy. Channels 2013, 7:221-224.
109. McGee S.L., Mustard K.J., Hardie D.G., Baar K. Normal hypertrophy accompanied by phosphoryation and activation of AMP-activated protein kinase α1 following overload in LKB1 knockout mice. J Physiol 2008, 586:1731-1741.
110. Ferey J.L.A., Brault J.J., Smith C.A.S., Witczak C.A. Constitutive activation of CaMKKα signaling is sufficient but not necessary for mTORC1 activation and growth in mouse skeletal muscle. Am J Physiol Endocrinol Metab 2015, [2014; in press]. 10.1152/ajpendo.00322.2014.
111. Corradetti M.N., Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 2006, 25:6347-6360.
112. Powers S.K., Jackson M.J. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev 2008, 88:1243-1276.
113. Smith L.W., Smith J.D., Criswell D.S. Involvement of nitric oxide synthase in skeletal muscle adaptation to chronic overload. J Appl Physiol 2002, 92:2005-2011.
114. Soltow Q.A., Betters J.L., Sellman J.E., Lira V.A., Long J.H., Criswell D.S. Ibuprofen inhibits skeletal muscle hypertrophy in rats. Med Sci Sports Exerc 2006, 38:840-846.
115. Soltow Q.A., Zeanah E.H., Lira V.A., Criswell D.S. Cessation of cyclic stretch induces atrophy of C2C12 myotubes. Biochem Biophys Res Commun 2013, 434:316-321.
116. Suzuki N., Motohashi N., Uezumi A., Fukada S.-I., Yoshimura T., Itoyama Y., et al. NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 2007, 117:2468-2476.
117. Jewell J.L., Russell R.C., Guan K.-L. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013, 14:133-139.
118. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
119. Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
120. +-ATPase. Science 2011, 334:678-683.
121. Efeyan A., Zoncu R., Sabatini D.M. Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med 2012, 18:524-533.
122. Anthony J.C., Yoshizawa F., Anthony T.G., Vary T.C., Jefferson L.S., Kimball S.R. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway. J Nutr 2000, 130:2413-2419.
123. Dickinson J.M., Fry C.S., Drummond M.J., Gundermann D.M., Walker D.K., Glynn E.L., et al. Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids. J Nutr 2011, 141:856-862.
124. MacKenzie M.G., Hamilton D.L., Murray J.T., Baar K. mVps34 is activated by an acute bout of resistance exercise. Biochem Soc Trans 2007, 035:1314-1316.
125. Gulati P., Gaspers L.D., Dann S.G., Joaquin M., Nobukuni T., Natt F., et al. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab 2008, 7:456-465.
126. Gran P., Cameron-Smith D. The actions of exogenous leucine on mTOR signalling and amino acid transporters in human myotubes. BMC Physiol 2011, 11:10.
127. Xu L., Salloum D., Medlin P.S., Saqcena M., Yellen P., Perrella B., et al. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem 2011, 286:25477-25486.
128. Yoon M.-S., Du G., Backer J.M., Frohman M.A., Chen J. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. J Cell Biol 2011, 195:435-447.
129. D'Souza R.F., Marworth J.F., Figueiredo V.C., Della Gatta P.A., Petersen A.C., Mitchell C.J., et al. Dose-dependent increases in p70S6K phosphorylation and intramuscular branched-chain amino acids in older men following resistance exercise and protein intake. Physiol Rep 2014, 2.
130. Enlow D.H. Principles of bone remodeling 1963, Charles C. Thomas, IL.
131. Bonewald L.F. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 2007, 1116:281-290.
132. Bonewald L.F. Generation and function of osteocyte dendritic processes. J Musculoskelet Neuronal Interact 2005, 5:321-324.
133. Lanyon L.E. Osteocytes, strain detection, bone modeling and remodeling. Calcif Tissue Int 1993, 53(Suppl. 1):S102-S106. [discussion S106-7].
134. Klein-Nulend J., Bakker A.D., Bacabac R.G., Vatsa A., Weinbaum S. Mechanosensation and transduction in osteocytes. Bone 2013, 54:182-190.
135. Loiselle A.E., Jiang J.X., Donahue H.J. Gap junction and hemichannel functions in osteocytes. Bone 2013, 54:205-212.
136. Qing H., Bonewald L.F. Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int J Oral Sci 2009, 1:59-65.
137. Frost H.M. Bone modeling and skeletal modeling errors 1973, Charles C. Thomas, IL.
138. Paic F., Igwe J.C., Nori R., Kronenberg M.S., Franceschetti T., Harrington P., et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone 2009, 45:682-692.
139. Charras G.T., Williams B.A., Sims S.M., Horton M.A. Estimating the sensitivity of mechanosensitive ion channels to membrane strain and tension. Biophys J 2004, 87:2870-2884.
140. Gong X., Fan Y., Zhang Y., Luo C., Duan X., Yang L., et al. Inserted rest period resensitizes MC3T3-E1 cells to fluid shear stress in a time-dependent manner via F-actin-regulated mechanosensitive channel(s). Biosci Biotechnol Biochem 2014, 78:565-573.
141. Chen N.X., Ryder K.D., Pavalko F.M., Turner C.H., Burr D.B., Qiu J., et al. Ca(2+) regulates fluid shear-induced cytoskeletal reorganization and gene expression in osteoblasts. Am J Physiol Cell Physiol 2000, 278:C989-C997.
142. Ryder K.D., Duncan R.L. Parathyroid hormone enhances fluid shear-induced [Ca2+]i signaling in osteoblastic cells through activation of mechanosensitive and voltage-sensitive Ca2+ channels. J Bone Miner Res 2001, 16:240-248.
143. Lieben L., Carmeliet G. The involvement of TRP channels in bone homeostasis. Front Endocrinol (Lausanne) 2012, 3:99.
144. Guilak F., Leddy H.A., Liedtke W. Transient receptor potential vanilloid 4: the sixth sense of the musculoskeletal system?. Ann N Y Acad Sci 2010, 1192:404-409.
145. Hill-Eubanks D.C., Gonzales A.L., Sonkusare S.K., Vascular Nelson M.T., TRP Channels: performing under pressure and going with the flow. Physiology (Bethesda) 2014, 29:343-360.
146. Mizoguchi F., Mizuno A., Hayata T., Nakashima K., Heller S., Ushida T., et al. Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. J Cell Physiol 2008, 216:47-53.
147. Nauli S.M., Alenghat F.J., Luo Y., Williams E., Vassilev P., Li X., et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003, 33:129-137.
148. Malicki J., Avidor-Reiss T. From the cytoplasm into the cilium: bon voyage. Organogenesis 2014, 10:138-157.
149. Patel A., Honore E. Polycystins and renovascular mechanosensory transduction. Nat Rev Nephrol 2010, 6:530-538.
150. Xiao Z., Dallas M., Qiu N., Nicolella D., Cao L., Johnson M., et al. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J 2011, 25:2418-2432.
151. Wang H., Sun W., Ma J., Pan Y., Wang L., Zhang W. Polycystin-1 mediates mechanical strain-induced osteoblastic mechanoresponses via potentiation of intracellular calcium and Akt/beta-catenin pathway. PLoS One 2014, 9:e91730.
152. McNamara L.M., Majeska R.J., Weinbaum S., Friedrich V., Schaffler M.B. Attachment of osteocyte cell processes to the bone matrix. Anat Rec (Hoboken) 2009, 292:355-363.
153. Zhou L., Bohn L.M. Functional selectivity of GPCR signaling in animals. Curr Opin Cell Biol 2014, 27:102-108.
154. Reich K.M., McAllister T.N., Gudi S., Frangos J.A. Activation of G proteins mediates flow-induced prostaglandin E2 production in osteoblasts. Endocrinology 1997, 138:1014-1018.
155. Chachisvilis M., Zhang Y.L., Frangos J.A. G protein-coupled receptors sense fluid shear stress in endothelial cells. Proc Natl Acad Sci U S A 2006, 103:15463-15468.
156. Zhang Y.L., Frangos J.A., Chachisvilis M. Mechanical stimulus alters conformation of type 1 parathyroid hormone receptor in bone cells. Am J Physiol Cell Physiol 2009, 296:C1391-C1399.
157. Gudi S., Nolan J.P., Frangos J.A. Modulation of GTPase activity of G proteins by fluid shear stress and phospholipid composition. Proc Natl Acad Sci U S A 1998, 95:2515-2519.
158. Yang Y., Tang L.Q., Wei W. Prostanoids receptors signaling in different diseases/cancers progression. J Recept Signal Transduct Res 2013, 33:14-27.
159. Thorsen K., Kristoffersson A.O., Lerner U.H., Lorentzon R.P. In situ microdialysis in bone tissue. Stimulation of prostaglandin E2 release by weight-bearing mechanical loading. J Clin Invest 1996, 98:2446-2449.
160. Forwood M.R., Kelly W.L., Worth N.F. Localisation of prostaglandin endoperoxide H synthase (PGHS)-1 and PGHS-2 in bone following mechanical loading in vivo. Anat Rec 1998, 252:580-586.
161. Forwood M.R. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 1996, 11:1688-1693.
162. Li J., Burr D.B., Turner C.H. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loading. Calcif Tissue Int 2002, 70:320-329.
163. Gong X., Yang W., Wang L., Duncan R.L., Pan J. Prostaglandin E2 modulates F-actin stress fiber in FSS-stimulated MC3T3-E1 cells in a PKA-dependent manner. Acta Biochim Biophys Sin (Shanghai) 2014, 46:40-47.
164. Castillo A.B., Triplett J.W., Pavalko F.M., Turner C.H. Estrogen receptor-beta regulates mechanical signaling in primary osteoblasts. Am J Physiol Endocrinol Metab 2014, 306:E937-E944.
165. Li Y., Luo Y., Huang K., Xing J., Xie Z., Lin M., et al. The responses of osteoblasts to fluid shear stress depend on substrate chemistries. Arch Biochem Biophys 2013, 539:38-50.
166. Batra N., Burra S., Siller-Jackson A.J., Gu S., Xia X., Weber G.F., et al. Mechanical stress-activated integrin alpha5beta1 induces opening of connexin 43 hemichannels. Proc Natl Acad Sci U S A 2012, 109:3359-3364.
167. Liu D., Genetos D.C., Shao Y., Geist D.J., Li J., Ke H.Z., et al. Activation of extracellular-signal regulated kinase (ERK1/2) by fluid shear is Ca(2+)- and ATP-dependent in MC3T3-E1 osteoblasts. Bone 2008, 42:644-652.
168. Li J., Liu D., Ke H.Z., Duncan R.L., Turner C.H. The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem 2005, 280:42952-42959.
169. Galea G.L., Sunters A., Meakin L.B., Zaman G., Sugiyama T., Lanyon L.E., et al. Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4. FEBS Lett 2011, 585:2450-2454.
170. Sanuki R., Mitsui N., Suzuki N., Koyama Y., Yamaguchi A., Isokawa K., et al. Effect of compressive force on the production of prostaglandin E(2) and its receptors in osteoblastic Saos-2 cells. Connect Tissue Res 2007, 48:246-253.
171. Bonewald L.F., Johnson M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 2008, 42:606-615.
172. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
173. Kikuchi A., Kishida S., Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med 2006, 38:1-10.
174. Hens J.R., Wilson K.M., Dann P., Chen X., Horowitz M.C., Wysolmerski J.J. TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 2005, 20:1103-1113.
175. Norvell S.M., Alvarez M., Bidwell J.P., Pavalko F.M. Fluid shear stress induces beta-catenin signaling in osteoblasts. Calcif Tissue Int 2004, 75:396-404.
176. Kamel M.A., Picconi J.L., Lara-Castillo N., Johnson M.L. Activation of beta-catenin signaling in MLO-Y4 osteocytic cells versus 2T3 osteoblastic cells by fluid flow shear stress and PGE2: implications for the study of mechanosensation in bone. Bone 2010, 47:872-881.
177. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006, 281:23698-23711.
178. Saxon L.K., Jackson B.F., Sugiyama T., Lanyon L.E., Price J.S. Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V High Bone Mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it. Bone 2011, 49:184-193.
179. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
180. Tu X., Rhee Y., Condon K.W., Bivi N., Allen M.R., Dwyer D., et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 2012, 50:209-217.
181. Morse A., McDonald M.M., Kelly N.H., Melville K.M., Schindeler A., Kramer I., et al. Mechanical Load increases in bone formation via a sclerostin-independent pathway. J Bone Miner Res 2014, 29:2456-2467.
182. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin Mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
183. Wang Y., Nishida S., Sakata T., Elalieh H.Z., Chang W., Halloran B.P., et al. Insulin-like growth factor-I is essential for embryonic bone development. Endocrinology 2006, 147:4753-4761.
184. Sheng M.H.C., Zhou X.-D., Bonewald L.F., Baylink D.J., Lau K.H.W. Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice. Bone 2013, 52:133-144.
185. Raab-Cullen D.M., Thiede M.A., Petersen D.N., Kimmel D.B., Recker R.R. Mechanical loading stimulates rapid changes in periosteal gene expression. Calcif Tissue Int 1994, 55:473-478.
186. Reijnders C.M.A., Bravenboer N., Tromp A.M., Blankenstein M.A., Lips P. Effect of mechanical loading on insulin-like growth factor-I gene expression in rat tibia. J Endocrinol 2007, 192:131-140.
187. Lean J.M., Jagger C.J., Chambers T.J., Chow J.W. Increased insulin-like growth factor I mRNA expression in rat osteocytes in response to mechanical stimulation. Am J Physiol 1995, 268:E318-E327.
188. Sakata T., Wang Y., Halloran B.P., Elalieh H.Z., Cao J., Bikle D.D. Skeletal unloading induces resistance to insulin-like growth factor-I (IGF-I) by inhibiting activation of the IGF-I signaling pathways. J Bone Miner Res 2004, 19:436-446.
189. Gross T.S., Srinivasan S., Liu C.C., Clemens T.L., Bain S.D. Noninvasive loading of the murine tibia: an in vivo model for the study of mechanotransduction. J Bone Miner Res 2002, 17:493-501.
190. Kesavan C., Wergedal J.E., Lau K.H., Mohan S. Conditional disruption of IGF-I gene in type 1alpha collagen-expressing cells shows an essential role of IGF-I in skeletal anabolic response to loading. Am J Physiol Endocrinol Metab 2011, 301:E1191-E1197.
191. Lau K.H., Baylink D.J., Zhou X.D., Rodriguez D., Bonewald L.F., Li Z., et al. Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity. Am J Physiol Endocrinol Metab 2013, 305:E271-E281.
192. Machwate M., Zerath E., Holy X., Pastoureau P., Marie P.J. Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 1994, 134:1031-1038.
193. Kubota T., Elalieh H.Z., Saless N., Fong C., Wang Y., Babey M., et al. Insulin-like growth factor-1 receptor in mature osteoblasts is required for periosteal bone formation induced by reloading. Acta Astronaut 2013, 92:73-78.
194. Klein-Nulend J., van Oers R.F., Bakker A.D., Bacabac R.G. Nitric oxide signaling in mechanical adaptation of bone. Osteoporos Int 2014, 25:1427-1437.
195. Gonzalez O., Fong K.D., Trindade M.C., Warren S.M., Longaker M.T., Smith R.L. Fluid shear stress magnitude, duration, and total applied load regulate gene expression and nitric oxide production in primary calvarial osteoblast cultures. Plast Reconstr Surg 2008, 122:419-428.
196. McGarry J.G., Klein-Nulend J., Prendergast P.J. The effect of cytoskeletal disruption on pulsatile fluid flow-induced nitric oxide and prostaglandin E2 release in osteocytes and osteoblasts. Biochem Biophys Res Commun 2005, 330:341-348.
197. McAllister T.N., Du T., Frangos J.A. Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells. Biochem Biophys Res Commun 2000, 270:643-648.
198. Turner C.H., Takano Y., Owan I., Murrell G.A. Nitric oxide inhibitor l-NAME suppresses mechanically induced bone formation in rats. Am J Physiol 1996, 270:E634-E639.
199. Watanuki M., Sakai A., Sakata T., Tsurukami H., Miwa M., Uchida Y., et al. Role of inducible nitric oxide synthase in skeletal adaptation to acute increases in mechanical loading. J Bone Miner Res 2002, 17:1015-1025.
200. Rahnert J., Fan X., Case N., Murphy T.C., Grassi F., Sen B., et al. The role of nitric oxide in the mechanical repression of RANKL in bone stromal cells. Bone 2008, 43:48-54.
201. Kitase Y., Barragan L., Qing H., Kondoh S., Jiang J.X., Johnson M.L., et al. Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the beta-catenin and PKA pathways. J Bone Miner Res 2010, 25:2657-2668.
202. Karim S.M., Sandler M., Williams E.D. Distribution of prostaglandins in human tissues. Br J Pharmacol Chemother 1967, 31:340-344.
203. Rodemann H.P., Goldberg A.L. Arachidonic acid, prostaglandin E2 and F2 alpha influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem 1982, 257:1632-1638.
204. Markworth J.F., Cameron-Smith D. Prostaglandin F2α stimulates PI3K/ERK/mTOR signaling and skeletal myotube hypertrophy. Am J Physiol Cell Physiol 2011, 300:C671-C682.
205. Smith R.H., Palmer R.M., Reeds P.J. Protein synthesis in isolated rabbit forelimb muscles. The possible role of metabolites of arachidonic acid in the response to intermittent stretching. Biochem J 1983, 214:153-161.
206. Markworth J.F., Cameron-Smith D. Arachidonic acid supplementation enhances in vitro skeletal muscle cell growth via a COX-2-dependent pathway. Am J Physiol Cell Physiol 2013, 304:C56-C67.
207. Korotkova M., Lundberg I.E. The skeletal muscle arachidonic acid cascade in health and inflammatory disease. Nat Rev Rheumatol 2014, 10:295-303.
208. Trappe T.A., Liu S.Z. Effects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise. J Appl Physiol 2013, 115:909-919.
209. Palmer R.M. Prostaglandins and the control of muscle protein synthesis and degradation. Prostaglandins Leukot Essent Fatty Acids 1990, 39:95-104.
210. Trappe T.A., White F., Lambert C.P., Cesar D., Hellerstein M., Evans W.J. Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am J Physiol Endocrinol Metab 2002, 282:E551-E556.
211. Novak M.L., Billich W., Smith S.M., Sukhija K.B., McLoughlin T.J., Hornberger T.A., et al. COX-2 inhibitor reduces skeletal muscle hypertrophy in mice. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1132-R1139.
212. von Maltzahn J., Chang N.C., Bentzinger C.F., Rudnicki M.A. Wnt signaling in myogenesis. Trends Cell Biol 2012, 22:602-609.
213. Tsivitse S. Notch and Wnt signaling, physiological stimuli and postnatal myogenesis. Int J Biol Sci 2010, 6:268-281.
214. Aschenbach W.G., Ho R.C., Sakamoto K., Fujii N., Li Y., Kim Y.-B., et al. Regulation of Dishevelled and beta-catenin in rat skeletal muscle: an alternative exercise-induced GSK-3beta signaling pathway. Am J Physiol Endocrinol Metab 2006, 291:E152-E158.
215. Leal M.L., Lamas L., Aoki M.S., Ugrinowitsch C., Ramos M.S., Tricoli V., et al. Effect of different resistance-training regimens on the WNT-signaling pathway. Eur J Appl Physiol 2011, 111:2535-2545.
216. Armstrong D.D., Esser K.A. Wnt/{beta}-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy. Am J Physiol Cell Physiol 2005, 289:C853-C859.
217. Armstrong D.D., Wong V.L., Esser K.A. Expression of beta-catenin is necessary for physiological growth of adult skeletal muscle. Am J Physiol Cell Physiol 2006, 291:C185-C188.
218. von Maltzahn J., Bentzinger C.F., Rudnicki M.A. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat Cell Biol 2012, 14:186-191.
219. von Maltzahn J., Zinoviev R., Chang N.C., Bentzinger C.F., Rudnicki M.A. A truncated Wnt7a retains full biological activity in skeletal muscle. Nat Commun 2013, 4.
220. Phornphutkul C., Lee M., Voigt C., Wu K.-Y., Ehrlich M.G., Gruppuso P.A., et al. The effect of rapamycin on bone growth in rabbits. J Orthop Res 2009, 27:1157-1161.
221. Sanchez C., He Y.-Z. Bone growth during rapamycin therapy in young rats. BMC Pediatr 2009, 9:3.
222. Alvarez-Garcia O., Garcia-Lopez E., Loredo V., Gil-Pena H., Rodriguez-Suarez J., Ordonez F.A., et al. Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 2010, 78:561-568.
223. Álvarez-García Ó., García-López E., Loredo V., Gil-Peña H., Mejía-Gaviria N., Rodríguez-Suárez J., et al. Growth hormone improves growth retardation induced by rapamycin without blocking its antiproliferative and antiangiogenic effects on rat growth plate. PLoS One 2012, 7:e34788.
224. Phornphutkul C., Wu K.-Y., Auyeung V., Chen Q., Gruppuso P.A. mTOR signaling contributes to chondrocyte differentiation. Dev Dyn 2008, 237:702-712.
225. Guan Y., Yang X., Yang W., Charbonneau C., Chen Q. Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development. FASEB J 2014, 28(10):4470-4481.
226. Singha U.K., Jiang Y., Yu S., Luo M., Lu Y., Zhang J., et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 2008, 103:434-446.
227. Kim J., Jung Y., Sun H., Joseph J., Mishra A., Shiozawa Y., et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J Cell Biochem 2012, 113:220-228.
228. Chen J., Tu X., Esen E., Joeng K.S., Lin C., Arbeit J.M., et al. WNT7B promotes bone formation in part through mTORC1. PLoS Genet 2014, 10:e1004145.
229. Hadji P., Coleman R., Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol 2013, 87:101-111.